Crossmark

Gasotransmitters in cancer: from pathophysiology to experimental therapy

Crossref DOI link: https://doi.org/10.1038/nrd.2015.1

Published Online: 2015-12-18

Published Print: 2016-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Szabo, Csaba
License Information

Text and Data Mining valid from 2015-12-18
More Information

Article History

First Online: 18 December 2015

Competing interests

: The author is a principal and a shareholder of CBS Therapeutics Inc., a start-up company involved in the research and development of CBS inhibitors for cancer therapy.